Protective effects of metallothionein on isoniazid and rifampicin-induced hepatotoxicity in mice. 2013

Yong Lian, and Jing Zhao, and Peiyu Xu, and Yimei Wang, and Jun Zhao, and Li Jia, and Ze Fu, and Li Jing, and Gang Liu, and Shuangqing Peng
Evaluation and Research Centre for Toxicology, Institute of Disease Control and Prevention, Academy of Military Medical Sciences, Beijing, China.

Isoniazid (INH) and Rifampicin (RFP) are widely used in the world for the treatment of tuberculosis, but the hepatotoxicity is a major concern during clinical therapy. Previous studies showed that these drugs induced oxidative stress in liver, and several antioxidants abated this effect. Metallothionein (MT), a member of cysteine-rich protein, has been proposed as a potent antioxidant. This study attempts to determine whether endogenous expression of MT protects against INH and RFP-induced hepatic oxidative stress in mice. Wild type (MT+/+) and MT-null (MT-/-) mice were treated intragastrically with INH (150 mg/kg), RFP (300 mg/kg), or the combination (150 mg/kg INH +300 mg/kg RFP) for 21 days. The results showed that MT-/- mice were more sensitive than MT+/+ mice to INH and RFP-induced hepatic injuries as evidenced by hepatic histopathological alterations, increased serum AST levels and liver index, and hepatic oxidative stress as evidenced by the increase of MDA production and the change of liver antioxidant status. Furthermore, INH increased the protein expression of hepatic CYP2E1 and INH/RFP (alone or in combination) decreased the expression of hepatic CYP1A2. These findings clearly demonstrate that basal MT provides protection against INH and RFP-induced toxicity in hepatocytes. The CYP2E1 and CYP1A2 were involved in the pathogenesis of INH and RFP-induced hepatotoxicity.

UI MeSH Term Description Entries
D007538 Isoniazid Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. Isonicotinic Acid Hydrazide,Ftivazide,Isonex,Isonicotinic Acid Vanillylidenehydrazide,Phthivazid,Phthivazide,Tubazide,Acid Vanillylidenehydrazide, Isonicotinic,Hydrazide, Isonicotinic Acid,Vanillylidenehydrazide, Isonicotinic Acid
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D008668 Metallothionein A low-molecular-weight (approx. 10 kD) protein occurring in the cytoplasm of kidney cortex and liver. It is rich in cysteinyl residues and contains no aromatic amino acids. Metallothionein shows high affinity for bivalent heavy metals. Isometallothionein,Metallothionein A,Metallothionein B,Metallothionein I,Metallothionein II,Metallothionein IIA
D005978 Glutathione A tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides. Reduced Glutathione,gamma-L-Glu-L-Cys-Gly,gamma-L-Glutamyl-L-Cysteinylglycine,Glutathione, Reduced,gamma L Glu L Cys Gly,gamma L Glutamyl L Cysteinylglycine
D005979 Glutathione Peroxidase An enzyme catalyzing the oxidation of 2 moles of GLUTATHIONE in the presence of HYDROGEN PEROXIDE to yield oxidized glutathione and water. Cytosolic Glutathione Peroxidase,Glutathione Lipoperoxidase,Selenoglutathione Peroxidase,Glutathione Peroxidase, Cytosolic,Lipoperoxidase, Glutathione,Peroxidase, Glutathione,Peroxidase, Selenoglutathione
D000410 Alanine Transaminase An enzyme that catalyzes the conversion of L-alanine and 2-oxoglutarate to pyruvate and L-glutamate. (From Enzyme Nomenclature, 1992) EC 2.6.1.2. Alanine Aminotransferase,Glutamic-Pyruvic Transaminase,SGPT,Alanine-2-Oxoglutarate Aminotransferase,Glutamic-Alanine Transaminase,Alanine 2 Oxoglutarate Aminotransferase,Aminotransferase, Alanine,Aminotransferase, Alanine-2-Oxoglutarate,Glutamic Alanine Transaminase,Glutamic Pyruvic Transaminase,Transaminase, Alanine,Transaminase, Glutamic-Alanine,Transaminase, Glutamic-Pyruvic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000975 Antioxidants Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. Anti-Oxidant,Antioxidant,Antioxidant Activity,Endogenous Antioxidant,Endogenous Antioxidants,Anti-Oxidant Effect,Anti-Oxidant Effects,Anti-Oxidants,Antioxidant Effect,Antioxidant Effects,Activity, Antioxidant,Anti Oxidant,Anti Oxidant Effect,Anti Oxidant Effects,Anti Oxidants,Antioxidant, Endogenous,Antioxidants, Endogenous
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular

Related Publications

Yong Lian, and Jing Zhao, and Peiyu Xu, and Yimei Wang, and Jun Zhao, and Li Jia, and Ze Fu, and Li Jing, and Gang Liu, and Shuangqing Peng
July 2013, The AAPS journal,
Yong Lian, and Jing Zhao, and Peiyu Xu, and Yimei Wang, and Jun Zhao, and Li Jia, and Ze Fu, and Li Jing, and Gang Liu, and Shuangqing Peng
October 2014, Journal of natural products,
Yong Lian, and Jing Zhao, and Peiyu Xu, and Yimei Wang, and Jun Zhao, and Li Jia, and Ze Fu, and Li Jing, and Gang Liu, and Shuangqing Peng
November 2015, Bioorganic & medicinal chemistry letters,
Yong Lian, and Jing Zhao, and Peiyu Xu, and Yimei Wang, and Jun Zhao, and Li Jia, and Ze Fu, and Li Jing, and Gang Liu, and Shuangqing Peng
February 2000, Fitoterapia,
Yong Lian, and Jing Zhao, and Peiyu Xu, and Yimei Wang, and Jun Zhao, and Li Jia, and Ze Fu, and Li Jing, and Gang Liu, and Shuangqing Peng
May 2011, European journal of pharmacology,
Yong Lian, and Jing Zhao, and Peiyu Xu, and Yimei Wang, and Jun Zhao, and Li Jia, and Ze Fu, and Li Jing, and Gang Liu, and Shuangqing Peng
October 2009, Toxicology,
Yong Lian, and Jing Zhao, and Peiyu Xu, and Yimei Wang, and Jun Zhao, and Li Jia, and Ze Fu, and Li Jing, and Gang Liu, and Shuangqing Peng
July 2013, Current drug metabolism,
Yong Lian, and Jing Zhao, and Peiyu Xu, and Yimei Wang, and Jun Zhao, and Li Jia, and Ze Fu, and Li Jing, and Gang Liu, and Shuangqing Peng
May 1975, The Journal of pediatrics,
Yong Lian, and Jing Zhao, and Peiyu Xu, and Yimei Wang, and Jun Zhao, and Li Jia, and Ze Fu, and Li Jing, and Gang Liu, and Shuangqing Peng
February 1978, Gastroenterologie clinique et biologique,
Yong Lian, and Jing Zhao, and Peiyu Xu, and Yimei Wang, and Jun Zhao, and Li Jia, and Ze Fu, and Li Jing, and Gang Liu, and Shuangqing Peng
April 2011, Pakistan journal of pharmaceutical sciences,
Copied contents to your clipboard!